BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026

BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its first quarter 2026 financial results on Thursday, May 14, 2026, and will host a conference call and webcast at 4:30 PM ET.

The webcast will feature an overview of the quarter from BioStem Technologies management. To register for the event, please click HERE .

Conference Call & Webcast Information:

Conference ID: 9695874

North America Toll-Free: (800) 715-9871

International Toll: +1 (646) 307-1963

Webcast Link: https://events.q4inc.com/attendee/844730655

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain ® , CryoTek ® and SteriTek ® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). BioStem’s portfolio of quality brands includes its Neox ® , Clarix ® , VENDAJE ® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media: To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .

Contact BioStem: Website: www.biostemtechnologies.com E-Mail: [email protected] X: @BSEM_Tech Facebook: BioStemTechnologies Phone: 954-380-8342

Investor Relations: Philip Trip Taylor, Gilmartin Group E-Mail: [email protected]

Public Relations: Jennifer Horton, Relevance [email protected]